DE10199015I2 - Mitteln zur Modulierung von Verfahren durch Retinoid Rezeptoren und dafür nützliche Verbindungen. - Google Patents

Mitteln zur Modulierung von Verfahren durch Retinoid Rezeptoren und dafür nützliche Verbindungen.

Info

Publication number
DE10199015I2
DE10199015I2 DE2001199015 DE10199015C DE10199015I2 DE 10199015 I2 DE10199015 I2 DE 10199015I2 DE 2001199015 DE2001199015 DE 2001199015 DE 10199015 C DE10199015 C DE 10199015C DE 10199015 I2 DE10199015 I2 DE 10199015I2
Authority
DE
Germany
Prior art keywords
ligands
retinoid
agents
compounds useful
retinoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2001199015
Other languages
English (en)
Other versions
DE10199015I1 (de
Inventor
Ronald Evans
David Mangelsdorf
Richard Heyman
Marcus Boehm
Gregor Eichele
Christina Thaller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Ligand Pharmaceuticals Inc
Salk Institute for Biological Studies
Original Assignee
Baylor College of Medicine
Ligand Pharmaceuticals Inc
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25202656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10199015(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baylor College of Medicine, Ligand Pharmaceuticals Inc, Salk Institute for Biological Studies filed Critical Baylor College of Medicine
Application granted granted Critical
Publication of DE10199015I1 publication Critical patent/DE10199015I1/de
Publication of DE10199015I2 publication Critical patent/DE10199015I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/26—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/46—Unsaturated compounds containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/80—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE2001199015 1991-12-18 1992-12-18 Mitteln zur Modulierung von Verfahren durch Retinoid Rezeptoren und dafür nützliche Verbindungen. Active DE10199015I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80998091A 1991-12-18 1991-12-18
PCT/US1992/011214 WO1993011755A1 (en) 1991-12-18 1992-12-18 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor

Publications (2)

Publication Number Publication Date
DE10199015I1 DE10199015I1 (de) 2001-05-10
DE10199015I2 true DE10199015I2 (de) 2004-01-29

Family

ID=25202656

Family Applications (4)

Application Number Title Priority Date Filing Date
DE2001199015 Active DE10199015I2 (de) 1991-12-18 1992-12-18 Mitteln zur Modulierung von Verfahren durch Retinoid Rezeptoren und dafür nützliche Verbindungen.
DE69224660T Expired - Lifetime DE69224660C5 (de) 1991-12-18 1992-12-18 Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen
DE69233768T Revoked DE69233768D1 (de) 1991-12-18 1992-12-18 Retinsäurederivate
DE0617614T Pending DE617614T1 (de) 1991-12-18 1992-12-18 Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE69224660T Expired - Lifetime DE69224660C5 (de) 1991-12-18 1992-12-18 Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen
DE69233768T Revoked DE69233768D1 (de) 1991-12-18 1992-12-18 Retinsäurederivate
DE0617614T Pending DE617614T1 (de) 1991-12-18 1992-12-18 Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.

Country Status (11)

Country Link
EP (2) EP0617614B1 (de)
JP (2) JP4001618B2 (de)
AT (2) ATE439341T1 (de)
AU (1) AU679171B2 (de)
CA (1) CA2123223C (de)
DE (4) DE10199015I2 (de)
DK (1) DK0617614T3 (de)
ES (1) ES2066750T3 (de)
LU (1) LU90752I2 (de)
NL (1) NL300043I2 (de)
WO (1) WO1993011755A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968989A (en) 1991-12-18 1999-10-19 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7056954B2 (en) 1991-12-18 2006-06-06 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
CZ282548B6 (cs) * 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
WO1995004036A1 (en) * 1993-01-11 1995-02-09 Ligand Pharmaceuticals Inc. Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5585244A (en) * 1994-06-10 1996-12-17 Ligand Pharmaceuticals Incorporated Detection of retinoid X receptor subtype γ proteins
WO1996023070A2 (en) * 1995-01-23 1996-08-01 Ligand Pharmaceuticals Incorporated HUMAN RETINOID X RECEPTOR - GAMMA (hRXR-GAMMA)
CA2204616C (en) 1995-09-18 2002-12-17 Ranjan Mukherjee Ppar gamma antagonists for treating obesity
US5998654A (en) * 1997-07-25 1999-12-07 Ligand Pharmaceuticals Incorporated Retinoic acid receptor antagonist compounds and methods
EP1093362A1 (de) 1998-06-12 2001-04-25 Ligand Pharmaceuticals Incorporated Verwendung von rxr modulatoren zur behandlung von anti-östrogen-resistent brustkrebs
US6048873A (en) * 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6147224A (en) * 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6403638B1 (en) 1998-10-01 2002-06-11 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
FR2787789B1 (fr) * 1998-12-29 2002-06-14 Lipha Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
WO2000061233A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
WO2000061232A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
US6166244A (en) 1999-05-07 2000-12-26 Allergan Sales, Inc. Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity
US6177588B1 (en) 1999-05-07 2001-01-23 Allergan Sales, Inc. 1-alkoxy and 1-acyloxy substituted cyclohex-1-ene compounds and sulfur and 1-alkoxycarbonyl analogs having retinoid-like biological activity
US6127382A (en) * 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6093838A (en) * 1999-08-16 2000-07-25 Allergan Sales, Inc. Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
JP2003520226A (ja) 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
US6613917B1 (en) 2000-03-23 2003-09-02 Allergan, Inc. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
TWI281911B (en) * 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
US6369225B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6252090B1 (en) 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en) 2000-08-29 2002-04-30 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6387951B1 (en) 2000-08-29 2002-05-14 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6740676B2 (en) 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6620963B1 (en) 2002-09-19 2003-09-16 Allergan, Inc. TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
US6759547B1 (en) 2003-01-14 2004-07-06 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
US7019034B2 (en) 2003-01-28 2006-03-28 Allergan, Inc. Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en) 2003-02-04 2004-07-06 Allergan, Inc. 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en) 2003-04-03 2005-04-26 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en) 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
EP1701934B1 (de) 2003-12-26 2009-02-25 Allergan, Inc. DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR
US7476673B2 (en) 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
US20160263189A1 (en) 2013-10-23 2016-09-15 Acadia Pharmaceuticals Inc. Treatment of a neurodegenerative disease or disorder
MA54296A (fr) 2018-11-26 2021-10-06 Denali Therapeutics Inc Procédés de traitement du métabolisme lipidique dérégulé

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62215581A (ja) * 1986-03-18 1987-09-22 Koichi Shiyudo フラボンカルボン酸誘導体
US4885311A (en) * 1987-06-29 1989-12-05 Molecular Design International Topical transretinoids for treatment of acne and skin diseases
LU86969A1 (fr) * 1987-08-12 1989-03-08 Oreal Association de derives de pyrimidine et de retinoides en composants separes pour induire et stimuler la croissance des cheveux et diminuer leur chute
US4916250A (en) * 1988-10-31 1990-04-10 Loyola University Of Chicago Phosphonate reagent compositions
FR2641184B1 (fr) * 1988-12-30 1991-04-05 Oreal Composition pour induire et stimuler la croissance des cheveux et/ou freiner leur chute, a base de derives de pyrimidine et de filtres solaires
ES2022025A6 (es) * 1990-05-07 1991-11-16 Univ Valencia Estudi General Procedimiento para la preparacion de acidos retinoicos y sus derivados.
JP2948923B2 (ja) * 1990-12-27 1999-09-13 日清製粉株式会社 レチノイン酸およびその異性体の製造方法
CZ282548B6 (cs) 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek

Also Published As

Publication number Publication date
CA2123223C (en) 2001-10-09
DE69233768D1 (de) 2009-09-24
AU3421893A (en) 1993-07-19
NL300043I1 (nl) 2001-06-01
EP0807624B1 (de) 2009-08-12
EP0807624A3 (de) 1999-09-29
DE69224660D1 (de) 1998-04-09
EP0617614A1 (de) 1994-10-05
ES2066750T3 (es) 1998-07-01
DE69224660T2 (de) 1998-07-16
AU679171B2 (en) 1997-06-26
ATE163544T1 (de) 1998-03-15
LU90752I2 (fr) 2001-06-05
DE617614T1 (de) 1995-06-08
EP0617614B1 (de) 1998-03-04
JP4001618B2 (ja) 2007-10-31
NL300043I2 (nl) 2001-11-01
JP2007254481A (ja) 2007-10-04
CA2123223A1 (en) 1993-06-24
DE10199015I1 (de) 2001-05-10
DE69224660C5 (de) 2010-06-02
DK0617614T3 (da) 1998-09-28
ES2066750T1 (es) 1995-03-16
WO1993011755A1 (en) 1993-06-24
EP0807624A2 (de) 1997-11-19
ATE439341T1 (de) 2009-08-15
JPH08502238A (ja) 1996-03-12

Similar Documents

Publication Publication Date Title
DE10199015I2 (de) Mitteln zur Modulierung von Verfahren durch Retinoid Rezeptoren und dafür nützliche Verbindungen.
DE69034269D1 (de) Neues Verfahren zur Erschliessung des immunologischen Repertoirs
DE69627193D1 (de) Dimer-selektive rxr modulatoren und verfahren zu ihrer verwendung
CA2075182A1 (en) Retinoid receptor compositions and methods
DE69315493D1 (de) Verfahren zur Oligomerisierung von leichten Alpha-Olefinen durch Oligomerisierung von Ethylen
DE69028513D1 (de) Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür
ATE366744T1 (de) Verknüpftes d-protein und verfahren zur identifizierung von rezeptor aktivität modulierenden verbindungen
DE69129115D1 (de) Neues verfahren zur behandlung von depression
ATE172247T1 (de) Car-rezeptoren und verwandte moleküle und entsprechende methoden
DE58906063D1 (de) Verfahren zum Einrichten von über Koppelvielfache einer mehrstufigen Koppelanordnung verlaufenden virtuellen Verbindungen.
DE69327059T2 (de) Verfahren zur herstellung von testelementen
DE69308407T2 (de) Verfahren zur automatischen Erzeugung von Prüfsequenzen
ATE206714T1 (de) Kombinatorisches verfahren zur identifizierung von organometallischen polymerisationskatalysatoren
DE69226638T2 (de) Verfahren zur trennung von gibberellinmischungen
ATE93516T1 (de) Verfahren zur resolution von threo-3-((2aminophenyl)-thio>-2-hydroxy-3-(4-methoxyphenyl)propions|ure.
DE69707318D1 (de) Trennung von 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylexancarbonsäure
ATE90338T1 (de) Verfahren zur herstellung von cypermethrinisomeren.
ES2004322T3 (es) Masas reveladoras de colores.
RU95103687A (ru) Способ прокалки флюса
ATA141089A (de) Verfahren zur einmischung von wasserstoffperoxidloesung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8310 Action for declaration of annulment